ACRES, ActivMed Focus on Site Accreditation, Standards
ActivMed will participate in ACRES ongoing Site Accreditation and Standards Initiative (SASI) to improve performance of global research sites through shared standards, accreditation, training and support.
The Alliance for Clinical Research Excellence and Safety (ACRES), a Massachusetts-based non-profit organization building a global system for clinical research and ActivMed Practices & Research, Inc., a woman-owned, for-profit, multi-specialty, free standing research organization based in Massachusetts and New Hampshire, announced a strategic alliance. ActivMed will participate in ACRES ongoing Site Accreditation and Standards Initiative (SASI) to improve performance of global research sites through shared standards, accreditation, training and support.
ActivMed participation will start with membership in a Phase III standards domain team involving personnel and professionalism criteria. With access to nearly one million patients in the Northeast region and a full range of clinical research studies (Phase I, II, III, IIIb and IV) performed on an inpatient and outpatient basis, ActivMed will also collaborate with ACRES in the testing of developed standards and processes for ACRES site accreditation work, professional development programs for research staff that can be offered within local communities as well as on line and the development of education and training programs ongoing at reasonable costs.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
